APMAdvances in Precision Medicine2424-85922424-9106Bio-Byword Scientific Publishing Pty. Ltd.10.18063/APM.2016.01.002Perspective ArticleCollaboration for success: the value of strategic col-laborations for precision medicine and biomarker discoveryhttps://artdesignp.com/journal/APM/1/1/10.18063/APM.2016.01.002LandeckLilla,LesslMonika,ReischlJoachim,BuschAndreas,CarriganPatricia,GottwaldMatthias,ReinkePetra,AsadullahKhusru2016112016-03-18Precision medicine aims to provide the precise treatment for the patient with the right dose at the right point  of time. Biomarkers (BM) are vital for the identification of patients who would benefit the most from individualized  treatment. In addition, they help to enable the prediction of prognosis, the detection of early therapeutic and adverse  effects, and may serve as surrogate endpoints in clinical trials. BM are becoming essential tools to increase productivity  in drug discovery and impressively enhance the way medicine is practiced. However, the identification, sufficient validation and implementation of such BM are challenging. This process requires expertise from different areas and high  resource investments. Collaborations of different partners may be helpful to overcome these challenges. In the past  decade, collaborations between diagnostics and pharmaceutical companies as well as industrial–academic collaborations have been increasingly pursued. Moreover, public funding may offer support and open new opportunities to form  such consortia. Herein we give an overview of the different types of collaborations, their opportunities and challenges, and describe experiences in forming strategic partnerships with other companies.precision medicine, consortia, drug discovery, patient selection, public funding

1. Landeck L, Kneip C, Reischl J, et al. 2015, Biomarkers and personalized medicine: current status and further perspectives with special focus on dermatology, in Experimental Dermatology. (In press) 2. Scannell J W, Blanckley A, Boldon H, et al. 2012, Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews Drug Discovery, vol.11: 191-200. 3. Arrowsmith J, 2011, Phase II failures: 2008-2010. Nature Reviews Drug Discovery, vol.10: 328-329. 4. Salter H and Holland R, 2014, Biomarkers: refining diagnosis and expediting drug development -- reality, aspiration and the role of open innovation. Journal of Internal Medicine, vol.276: 215-228. 5. Bettegowda C, Sausen M, Leary R J, et al. 2014, Detection of circulating tumor DNA in early- and late-stage human malignancies. Science Translational Medicine, vol.6: 224. 6. Diehl F, Li M, He Y, et al. 2006, BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nature Methods, vol.3: 551-559. 7. Lessl M, Bryans J S, Richards D, et al. 2011, Crowd sourcing in drug discovery. Nature Reviews Drug Discovery, vol.10: 241-242. 8. Wellenreuther R, Keppler D, Mumberg D, et al. 2012, Promoting drug discovery by collaborative innovation: A novel risk- and reward-sharing partnership between the German Cancer Research Center and Bayer HealthCare. Drug Discovery Today, vol.17: 1242-1248. 9. Lessl M, Schoepe S, Sommer A, et al. 2011. Granist-targets -- an innovative approach to translate ideas from basic research into novel drugs. Drug Discovery Today, vol.16: 288-292. 10. Dorsch H, Jurock A E, Schoepe S, et al. 2015, Grants4Targets — an open innovation initiative to foster drug discovery collaborations between academia and the pharmaceutical industry. Nature Reviews Drug Discovery, vol.14: 74–76. 11. Schmitz A A, Hackethal S, Schulz A, et al. 2015, Pharma compound sharing with academia: experiences with providing Vitamin D receptor ligands. Nature Reviews Drug Discovery, vol.14: 294–296. 12. Asadullah K, Busch A, Gottwald G, et al. 2015, Industrial–academic collaborations for biomarkers. Nature Reviews Drug Discovery, vol.14: 805–806. 13. Wholley D, 2014, The biomarkers consortium. Nature Reviews Drug Discovery, vol.13: 791–792. 14. Stephenson D, Sauer J M, 2014, The predictive safety testing consortium and the coalition against major diseases. Nature Reviews Drug Discovery, vol.13: 793–794. 15. Lessl M, Douglas F, 2010, From technology-transfer to know-how interchange. Wissenschaftsmanagement, vol.(2): 34–41.